Chronic Myelogenous Leukemia (CML) — VA Rating (DC 7719)
Diagnostic Code 7719 · 38 CFR §4.117
What Is It?
Chronic myelogenous leukemia (CML) is a cancer of the bone marrow where a genetic mutation (Philadelphia chromosome) causes overproduction of myeloid white blood cells. CML progresses through three phases: chronic phase (manageable), accelerated phase (worsening), and blast crisis (acute leukemia). Modern treatment with tyrosine kinase inhibitors (such as imatinib) has transformed CML into a manageable chronic condition for many patients, but lifelong treatment is typically required. For veterans, CML may be linked to radiation exposure, benzene exposure, or other toxic exposures during service.
Rating Criteria
| Rating | Criteria |
|---|---|
| 100% | Active CML or during treatment. When the disease is in complete molecular remission on maintenance therapy, the VA reassesses based on treatment requirements and residual effects. |
Evidence Needed
Blood tests and bone marrow biopsy confirming the Philadelphia chromosome or BCR-ABL mutation are diagnostic. Hematology and oncology treatment records documenting the treatment regimen are needed. Service records showing radiation or chemical exposure help establish nexus. A nexus opinion from an oncologist or hematologist is recommended for non-presumptive claims.
C&P Exam Tips
Describe your current treatment (usually a daily oral medication) and any side effects such as fatigue, nausea, edema, or muscle cramps. Explain the monitoring required — regular blood tests and periodic bone marrow biopsies. Describe how the condition and treatment affect daily functioning.
How to File
File on VA Form 21-526EZ with DC 7719. Submit diagnostic pathology, treatment records, and exposure documentation. Explore whether the condition qualifies under any presumptive lists.
Common Mistakes
Not filing because CML is manageable with medication — the condition still warrants a 100 percent rating during active disease. Not documenting medication side effects limits secondary claims.
Frequently Asked Questions
Will my rating be reduced if CML responds to medication?
The VA may reassess after a period of stable remission. However, the need for ongoing daily medication and monitoring typically supports a continued rating. Work with your VSO if a reduction is proposed.